PHVS Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 1.6%, SMA50 3.95%, SMA200 23.74%). The stock’s 14-day RSI is 53.92 (neutral), while the ATR of 1.55 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.04% below its high and over 127.72% above its low. Average 10-day trading volume of 194.26 thousand shares is below the 3-month average of 329.21 thousand, indicating normal recent market interest.

Pharvaris N.V. has 64.30 million shares outstanding. The public float is 37.11 million shares, elevated short interest at 0.76% of float. This equals 404.97 thousand shares. The short ratio is 3.54 days. Institutional investors hold 80.64% of the float. Insiders own 5.32%.

Pharvaris N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.03. This means the shares are trading above this model’s fair value.

Pharvaris N.V. (NASDAQ:PHVS) closed at $27.23 USD, gaining $1.02 (3.87%) from the previous close of $26.21. The stock is currently mid-range between its 52-week high and low $11.51 and $29.80. With a market capitalization of about $1.77 billion, Pharvaris N.V. is classified as a small-cap and shows lower-than-market volatility (beta ~-2.79). Key stats such as the average daily volume over the past year has been around 338.61 thousand shares, volume is running light vs its 52-week average. Headquartered in Leiden, None, Pharvaris N.V. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Berndt Axel Edvard Modig, the company employs approximately 108 people and listed since February 05, 2021. Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.

Pharvaris N.V. generated EPS of -$3.22 over the past year. Five-year average earnings growth is -7.73%. Wall Street analysts project EPS growth of 4.17% annually over the next five years. The latest quarter delivered EPS of -$0.70. The next quarter is forecast at -$0.71. Next year's EPS is expected at $4.06. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 4 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $27.00. The high target offers 128.92% upside. The low target suggests 3.01% downside. The mean target is $45.85. This offers 74.93% upside. Pharvaris N.V. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 12, 2025, missed forecasts by -10.26%. The prior quarter beat by 8.05%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 08, 2024.

Pharvaris N.V. (NASDAQ:PHVS) shares are flat -5.55% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Pharvaris N.V. trading at a premium to the broader market with a P/E of -8.41. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $30.24, suggesting 15.38% upside. Our AI forecast model points to short-term weakness (-0.08% over two weeks), a medium-term fall (-12.86% over three months), and a longer-term gain (5.84% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Pharvaris N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.08%, with price expected at $26.19 by February 03, 2026, within a range of $24.71 to $27.77 3-Month Outlook: Projected fall of -12.86%, reaching $22.84 by April 16, 2026, with a range of $21.91 to $23.83. 1-Year Outlook: Projected gain of 5.84%, with price at $27.74 by January 15, 2027, within a range of $26.03 to $29.71.

Pharvaris N.V. trades at a P/E ratio of -8.41, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.47 trading at moderately above to book value. The P/FCF stands at -10.84, also above market averages.